BCR-ABL-IN-5
Modify Date: 2025-08-21 02:04:29
BCR-ABL-IN-5 structure
|
Common Name | BCR-ABL-IN-5 | ||
|---|---|---|---|---|
| CAS Number | 1795736-60-5 | Molecular Weight | 494.37 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C25H21Cl2N5O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of BCR-ABL-IN-5BCR-ABL-IN-5 (compound II) is a Bcr-Abl kinase (Breakpoint cluster region-Abelson) inhibitor. BCR-ABL-IN-5 inhibits Bcr-AblWT and Bcr-AblT3151 with the IC50 value of 0.014 μM and 0.45 μM, respectively. BCR-ABL-IN-5 has some anti-proliferative activity against leukemic cells[1]. |
| Name | BCR-ABL-IN-5 |
|---|
| Description | BCR-ABL-IN-5 (compound II) is a Bcr-Abl kinase (Breakpoint cluster region-Abelson) inhibitor. BCR-ABL-IN-5 inhibits Bcr-AblWT and Bcr-AblT3151 with the IC50 value of 0.014 μM and 0.45 μM, respectively. BCR-ABL-IN-5 has some anti-proliferative activity against leukemic cells[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 6.5 μM (K562)[1]. |
| In Vitro | BCR-ABL-IN-5 (compound II) (0-100 mM, 72 hours) can inhibit the proliferation of K562 human leukemia cells[1]. Cell Proliferation Assay[1] Cell Line: K562 human leukemia cell line Concentration: 0-100 μM Incubation Time: 72 hours Result: Inhibited K562 proliferation with an IC50 value of 6.5 μM. |
| References |
| Molecular Formula | C25H21Cl2N5O2 |
|---|---|
| Molecular Weight | 494.37 |